Giacor Consulting, Inc.

11/14/2024

📢 Industry Updates to Watch

The final quarter of 2024 brings key developments in pharma & biotech. Key highlights include FDA approval decisions expected soon, Merck’s $588M acquisition to protect Keytruda, and BeiGene’s rebrand to BeOne Medicines.

🔹 FDA Approvals Watch:

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

11/14/2024

🔬 Bridging Talent and Innovation in Pharma & Biotech 🔬

At Giacor Consulting, we understand the unique needs of the pharmaceutical and biotechnology industries. Our specialized executive search and recruiting services connect the brightest minds with organizations at the forefront of life-saving advancements. Whether it’s a strategic commercial leadership role or a critical medical affairs position, our goal is to support innovation by securing the right talent.

Call now to connect with business.

12/20/2017

A US senator calls out a little biotech for price gouging. But will it change anything?

A little known biotech called Strongbridge Biopharma has attracted the attention of a prominent US senator who would like to make the company the latest poster child for price gouging in the pharma world. Earlier this week the Washington Post published a report which detailed how Strongbridge obtain...

01/13/2016

Biden to lead mooshot to cure cancer Pfizer/Allergan merger will create best pipeline in the industry, CEO says American Medical Association invests in health tech startup

12/15/2015

Sanofi is in exclusive talks to swap assets with Germany’s Boehringer Ingelheim GmbH in a 22.8 billion-euro ($25 billion) transaction that would be the largest for the French drugmaker in more than a decade.

09/23/2015

Heron Therapeutics (NASDAQ:HRTX) pops 25% after hours on robust volume in response to its announcement of positive results in a Phase 2 clinical trial assessing its investigational HTX-011 f

04/08/2015

http://www.pharmatimes.com/Article/15-04-08/US_filing_for_Gilead_s_next-gen_HIV_drug.aspx Original Source

03/11/2015

http://feedproxy.google.com/~r/MMMNews/~3/-_ad184DE0Y/ Original Source

03/04/2015

If that doesn’t feel like enough, change these three things.

07/30/2014

Bags immediate sales under the deal

10/17/2013

Isis receives milestone payment from Biogen Idec for advancement of dystrophy drug - bit.ly/1fFt6Oy

US-based drug developer Isis Pharmaceuticals has obtained a $10m payment from Biogen Idec for the development of a potential treatment for myotonic dystrophy, a chronic, slowly progressing, highly variable, inherited multisystemic disease.The...